| |
| |
|
| Insider
Information: |
Greene Barry E |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
132,162 |
|
|
Indirect Shares
|
6,153,503 |
|
|
| Direct
Value |
$10,630,500 |
|
|
|
Indirect Value
|
$12,262,113 |
|
|
| Total
Shares |
6,285,665 |
|
|
| Total
Value |
$22,892,613 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
President |
2020-09-09 |
70,343 |
2020-09-09 |
3,003 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director, 10% Owner |
2012-10-10 |
0 |
2012-10-10 |
6,150,500 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-08-11 |
13,606 |
2015-04-02 |
0 |
Premium* |
|
|
Acorda Therapeutics Inc |
ACOR |
Director |
2018-05-21 |
1,273 |
2017-01-03 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2022-11-10 |
46,940 |
2021-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-07-07 |
4 |
AS |
$159.99 |
$3,562,177 |
D/D |
(22,265) |
62,236 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-05-06 |
4 |
AS |
$149.99 |
$3,339,527 |
D/D |
(22,265) |
62,236 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2018-03-14 |
4 |
AS |
$140.43 |
$5,503,736 |
D/D |
(38,460) |
61,968 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2015-05-26 |
4 |
AS |
$125.00 |
$8,422,375 |
D/D |
(67,379) |
23,392 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-10-02 |
4 |
AS |
$125.00 |
$10,664,500 |
D/D |
(85,316) |
100,428 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-09-09 |
4 |
AS |
$122.66 |
$5,487,594 |
D/D |
(44,530) |
70,343 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-04-07 |
4 |
D |
$104.75 |
$174,321 |
D/D |
(1,663) |
62,236 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2014-11-11 |
4 |
AS |
$100.00 |
$1,110,000 |
D/D |
(11,100) |
33,592 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2014-12-19 |
4 |
AS |
$100.00 |
$1,120,000 |
D/D |
(11,200) |
22,392 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-09-20 |
4 |
AS |
$100.00 |
$7,681,500 |
D/D |
(76,815) |
88,584 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2019-10-22 |
4 |
AS |
$89.99 |
$5,301,581 |
D/D |
(58,913) |
52,938 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2014-11-17 |
4 |
AS |
$89.11 |
$2,975,780 |
D/D |
(33,200) |
33,592 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2014-02-03 |
4 |
D |
$78.68 |
$132,182 |
D/D |
(1,680) |
33,592 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
President and CEO |
• • – |
2021-06-16 |
4 |
B |
$56.32 |
$495,627 |
D/D |
8,800 |
8,800 |
0.01 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
President and CEO |
• • – |
2021-08-05 |
4 |
B |
$43.15 |
$1,020,054 |
D/D |
23,640 |
32,440 |
0.01 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2016-12-01 |
4 |
AS |
$42.61 |
$1,368,128 |
D/D |
(31,825) |
88,584 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2020-08-10 |
4 |
OE |
$42.22 |
$349,871 |
D/D |
4,931 |
67,167 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
President and CEO |
• • – |
2022-11-10 |
4 |
B |
$34.48 |
$500,022 |
D/D |
14,500 |
46,940 |
0.01 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2008-08-13 |
4 |
AS |
$33.92 |
$1,202,726 |
D/D |
(35,440) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President |
• – – |
2017-09-20 |
4 |
OE |
$31.39 |
$2,411,223 |
D/D |
76,815 |
165,399 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO |
• – – |
2007-10-24 |
4 |
AS |
$31.36 |
$165,126 |
D/D |
(5,220) |
4,551 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO |
• – – |
2007-10-24 |
4 |
AS |
$30.95 |
$329,373 |
D/D |
(10,580) |
9,771 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
COO |
• – – |
2007-10-24 |
4 |
AS |
$30.62 |
$669,359 |
D/D |
(21,700) |
20,351 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President and COO |
• – – |
2013-05-28 |
4 |
AS |
$30.00 |
$684,660 |
D/D |
(22,822) |
4,572 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2015-04-02 |
4 |
B |
$29.31 |
$87,938 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
